Development of a ferrocene-mediated needle-type glucose sensor covered with newly designed biocompatible membrane, 2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate.
To prepare the long-life and stable glucose sensor, we developed the ferrocene-mediated needle-type glucose sensor covered with newly designed biocompatible membrane, 2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate (MPC-co-BMA) membrane. In this membrane, the hydrophilic phosphorylcholine chains were grafted on the hydrophobic polymer surface. 1. The poly(MPC-co-BMA) membrane inhibited platelet activation and protein adhesion on the surface, showing excellent biocompatibility. These results suggested that the hydrophilic phospholipids chains might have the potential for suppressing activation and adsorption of biochemical molecules. 2. The ferrocene-mediated needle-type glucose sensor covered with poly(MPC-co-BMA) membrane achieved excellent results in vitro. Subcutaneous tissue glucose concentrations were measured in a wide range from 1.7 to more than 16.7 mmol/l. The correlation between subcutaneous tissue (Y) and blood (X) glucose concentrations was Y = 1.04X + 0.12 (r = 0.98). The subcutaneous tissue glucose concentrations could be monitored precisely for 7 days without any in vivo calibrations, and for 14 days by introducing in vivo calibrations. We therefore conclude that this sensor is stable and reliable, as compared to any other glucose sensors we developed.
Nishida
K
K
Department of Metabolic Medicine, Kumamoto University School of Medicine, Japan.
Sakakida
M
M
Ichinose
K
K
Uemura
T
T
Uehara
M
M
Kajiwara
K
K
Miyata
T
T
Shichiri
M
M
Ishihara
K
K
Nakabayashi
N
N
D000328:Adult; D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry; D015374:Biosensing Techniques; D001786:Blood Glucose / Q000032:analysis*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy; D004867:Equipment Design; D005296:Ferrous Compounds / Q000737:chemistry; D005947:Glucose / Q000032:analysis*; D006801:Humans; D066298:In Vitro Techniques; D007328:Insulin / Q000627:therapeutic use; D008567:Membranes, Artificial; D000075163:Metallocenes; D008689:Methacrylates / Q000737:chemistry; D008991:Monitoring, Physiologic / Q000295:instrumentation; D009339:Needles; D009942:Organometallic Compounds / Q000737:chemistry; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000737:chemistry; D015539:Platelet Activation; D010975:Platelet Aggregation Inhibitors; D011108:Polymers / Q000737:chemistry; D011485:Protein Binding; D012867:Skin / Q000737:chemistry; D013499:Surface Properties
D001672:Biocompatible Materials; D001786:Blood Glucose; D005296:Ferrous Compounds; D007328:Insulin; D008567:Membranes, Artificial; D000075163:Metallocenes; D008689:Methacrylates; D009942:Organometallic Compounds; D010975:Platelet Aggregation Inhibitors; D011108:Polymers; D010767:Phosphorylcholine; C070638:2-methacryloyloxyethyl phosphorylcholine; D005947:Glucose; C016284:butyl methacrylate; C004998:ferrocene